US FDA Approves J&J’s Blood Cancer Therapy
[ad_1]
(Reuters) – Johnson & Johnson stated on Thursday the U.S. Meals and Drug Administration had permitted its antibody-based remedy for sufferers with a difficult-to-treat sort of blood most cancers.
The remedy, talquetamab-tgvs branded as Talvey, belongs to a category known as bispecific antibodies designed to deliver a most cancers cell and an immune cell collectively so the physique’s immune system can kill the most cancers.
Talvey was permitted as a weekly or biweekly subcutaneous, or under-the-skin, injection, the corporate stated.
(Reporting by Mariam Sunny in Bengaluru; Enhancing by Krishna Chandra Eluri)
Copyright 2023 Thomson Reuters.
[ad_2]
Source link
